適用於治療曾接受過至少一次全身性療法，且帶有KRAS G12C突變之局部晚期或轉移性非小細胞肺癌(NSCLC)成年病人。

Antineoplastic Agent, KRAS Inhibitor

Distribution: 211 L.
Protein binding: 89%.
Metabolism: nonenzymatic conjugation and oxidative metabolism via CYP3As.
Half-life elimination: 5 hours.
Time to peak: median: 1 hour.
Excretion: feces: 74%; urine: 6%.
Clearance: 26.2 L/hour.

Hypersensitivity to sotorasib or any component of the formulation.

>10%: edema (15%), skin rash (12%), decreased serum albumin (22%), decreased serum calcium (35%), decreased serum sodium (28%), abdominal pain (15%), diarrhea (42%), nausea (26%), vomiting (17%), increase in urinary protein (29%), decreased hemoglobin (43%), lymphocytopenia (48%), prolonged partial thromboplastin time (23%), hepatotoxicity (25%), increased serum alanine aminotransferase (38%), increased serum alkaline phosphatase (33%), increased serum aspartate aminotransferase (39%), fatigue (26%), arthralgia (12%), musculoskeletal pain (35%), cough (20%), dyspnea (16%), pneumonia (12%).

960 mg (8 tab) once daily.

---

Recommended Lumakras dose reductions based on adverse reactions

dose	reduction dose
first dose reduction	480 mg (4 tab) once daily
second dose reduction	240 mg (2 tab) once daily

輕度至中度乾功能不全 (Child-Pugh A 或 B) 的病人，建議不做劑量調整。

重度肝功能不全 (Child-Pugh C) 建議增加不良反應的監測頻率。<20241115>